New hope for breast cancer: personalized Pre-Surgery drug combo shows promise
NCT ID NCT05101564
First seen Jan 30, 2026 · Last updated Jun 18, 2026 · Updated 25 times
Summary
This study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal was to see how the tumor's genetic makeup affects treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.